Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• DaTscan imaging resulted in a diagnostic change in 31% (95% CI (confidence interval): 22-42%) of patients with suspected Parkinsonian Syndrome (PS) and contributed to the differential diagnosis between neurodegenerative Parkinsonian Syndrome and non-dopamine deficiency causes of parkinsonism.
• DaTscan imaging influenced management decisions in 54% (95% CI: 47-61%) of patients with suspected PS, highlighting its clinical utility in modifying treatment plans based on diagnostic outcomes.
• No significant differences in effectiveness were identified across various population types or subgroups.
• Certain medications and drugs of abuse, including tobacco and alcohol, may affect striatal [(123)I]I-FP-CIT binding and impact the visual read of an [(123)I]I-FP-CIT SPECT scan, with a recommended but specialist-managed withdrawal prior to DaTscan imaging to reduce false-positive reporting.
• The reviewed studies do not specify any significant safety concerns or adverse effects associated with DaTscan use across different population types and subgroups.